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Biotransformation of steroidal ruscogenins (neoruscogenin and ruscogenin) was carried out with Cun-
ninghamella blakesleeana NRRL 1369 and endophytic fungus Neosartorya hiratsukae yielding mainly P450
monooxygenase products together with a glycosylated compound. Fermentation of ruscogenins (75:25,
neoruscogenin-ruscogenin mixture) with C. blakesleeana yielded 8 previously undescribed hydroxylated
compounds. Furthermore, microbial transformation of neoruscogenin by endophytic fungus N. hiratsukae
afforded three previously undescribed neoruscogenin derivatives. While hydroxylation at C-7, C-12, C-14,
C-21 with further oxidation at C-1 and C-7 were observed with C. blakesleeana, N. hiratsukae biotrans-
formation provided C-7 and C-12 hydroxylated compounds along with C-12 oxidized and C-1(O) gly-
cosylated derivatives. The structures of the metabolites were elucidated by 1-D (1H, 13C and DEPT135)
and 2-D NMR (COSY, HMBC, HMQC, NOESY, ROESY) as well as HR-MS analyses.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
The natural product drug discovery process involves isolation of
new metabolites from natural sources, investigation of their bio-
logical activities and semi-synthesis of more active analogs. Mi-
crobial transformation plays a vital role in the preparation of new
oxygenated derivatives due to the stereo- and regio-selective re-
action capability (Muffler et al., 2011; Swizdor et al., 2012; Wang
et al., 2015). Recently, the microbial biotransformation has been
used for numerous purposes: i) to overcome the problems
encountered in synthesis reactions; ii) to establish biosynthetic
pathways; iii) to increase/decrease the bioactivity/toxicity profiles
of the lead molecules; iv) to assist structure-activity relationship
studies (Chen et al., 2010a). In addition to these, it is a useful
method to model mammalian drug metabolism (Piska et al., 2016).
Metabolism of drugs is vital for the safety and efficacy, and the
microbial models are advantageous due to their competencesenabling researchers to identify minor metabolites. It has been
proven, that cytochrome P450 monooxygenase enzymes that exist
in all eukaryotic microorganisms, catalyze the hydroxylation of
steroidal compounds, especially Cunninghamella species (Asha and
Vidyavathi, 2009; Nelson, 1999).
In recent years, endophytic organisms attract great deal of
attention. They are bacterial or fungal microorganisms that colo-
nize living internal tissues of plants without causing any disease
symptoms, and they constitute one of the most exciting groups of
microorganisms. While producing novel bioactive compounds,
they can also interact with their hosts via special enzymes and
chemicals, which would make them useful sources as biocatalysts
for the biotransformation of natural products (Kumar and Ahmad,
2013; Suryanarayanan et al., 2012).
Ruscus aculeatus (Butcher's broom, Rusci rhizome, Aspar-
agaceae) have been used traditionally against chronic venous dis-
orders. Its extracts have strong anti-inflammatory activity, act as
anti-elastase, and decrease capillary permeability (Bouskela et al.,
1994; Facino et al., 1995). The major steroidal sapogenins, neo-
ruscogenin (NR) and ruscogenin (R), namely ruscogenins as a
mixture of 75:25 (NR:R), are the secondary metabolites responsible
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treat vascular disorders such as varicose and hemorrhoid. In various
pharmaceutical preparations, Ruscus dried root powders or its
hydroalcoholic extracts are used in combination with phenolic
compounds like trimethylhesperidin chalcone, ascorbic acid or
Melilotus officinalis extract for vascular health (Boyle et al., 2003;
Jawien et al., 2017). The European Pharmacopoeia prescribes not
less than 1.0% of total sapogenins expressed as ruscogenins, and
European Scientific Cooperative on Phytotherapy recommends oral
use of 7e11mg/day. However, there are still unknown matters in
regards to the absorption of the active substances after oral
administration, and whether they undergo hepatic metabolism
impairing their activity at lymphatic level (EMEA, 2008; ESCOP,
2003).
Biotransformation and semi-synthesis studies performed on
ruscogenins have so far been limited and there has been no report
on neoruscogenin (Chen et al., 2010a, 2010b). The aim of this study
was to estimate metabolism of ruscogenins and obtain new analogs
deriving from neoruscogenin. Herein, we report isolation and
structural elucidation of 11 previously undescribed biotransfor-
mation products of ruscogenins with diverse chemistry (Figs. 1 and
2).
2. Results and discussion
The literature survey prompted us to use C. blakesleeana as
biocatalyst to predict the possible metabolism products of the
major bioactive constituents of Ruscus aculeatus. Furthermore, in
order to reveal the potential use of endophytes as biocatalyst,
N. hiratsukaewas used to transform neoruscogenin. After 10 days of
incubation period, a number of compounds (1e10) were purified
from the microbial broths, and their structures were established by
1D, 2D NMR and HRMS experiments. The 1H and 13C NMR spectral
data of these compounds are presented in Tables 1e3.
2.1. Metabolite 1
In the HR-MS of 1, the major ion peak was observed at m/z
461.2899 [MþH]þ (calcd. 461.2903 for C27H41O6), indicating 8 de-
grees of unsaturation as in NR as well as the presence of twoFig. 1. Biotransformation products of ruscoghydroxyl groups due to 32 amu difference. Inspection of the 1H
NMR spectrum revealed additional signal at d 4.94, whereas two
new low-field carbon resonances appeared at d 67.3 and 86.8 in the
13C NMR spectrum, which were attributed to secondary and ter-
tiary alcohol groups based on the HSQC data. Detailed examination
of the COSY spectrum led to the deduction of 4 major spin systems
(SS): SS1 / H-1(O)/H2-2/H-3(O)/H2-4 (A ring); SS2 / H-6
(olefinic)/H-7(O)/H-8/H-9/H2-11/H2-12 (B and C rings); SS3/ H2-
15/H-16(O)/H-17/H-20/H3-21; SS4 / H2-23/H2-24 (allylic
coupling)/H2-27(allylic coupling)/H2-26(O) (Fig. 3). The SS2 corre-
lation between H-6 (d 5.97) and the new resonance appeared at
d 4.94 verified that the first hydroxylation was at C-7. The carbon
signal at d 86.8 was readily assigned to C-14 on the basis of a long-
distance correlationwith the singlet methyl proton ascribed for H3-
18 (d 1.20) and H2-15 (d 2.47 and 3.18) (Fig. 3). Moreover, separation
of the SS2 and SS3 due to the presence of a quaternary carbon (C-
14) verified the position of the second hydroxyl group.
In the 2D-NOESY spectrum, the correlation of alpha oriented H-
9 (d 2.45) with H-7 (d 4.94), and H-7's correlation with the
exchangeable proton of C-14(OH) (d 5.40) in turn, revealed the
relative configuration of C-7(OH) and C-14(OH) as b and a,
respectively (Fig. 4). Consequently, the structure of 1 was estab-
lished as 7b,14a-dihydroxy neoruscogenin.
2.2. Metabolite 2
The major ion peak at m/z 497.2531 [MþNa]þ (calcd. 497.2515
for C27H38O7Na) in the HR-MS spectrum of metabolite 2 displayed
46 amu increase compared to NR. In the 1H NMR spectrum of
metabolite 2, the observed resonances were mostly identical with
neoruscogenin, except a low-field signal at d 4.80 suggesting a
hydroxylation. In the 13C NMR spectrum, the chemical shift differ-
ences were more noticeable with a carbonyl signal at 201.0 ppm,
and a pair of tri-substituted olefinic system signals (d 128.4 and
165.6; deduced by HSQC and HMBC). Two additional carbon reso-
nances in the low-field were also noticed (d 71.6 and 86.9). The
significant down-field shift for one of the aforementioned double
bond resonances (d 165.6) suggested an alpha-beta unsaturated
ketone functionality in the structure. The absence of characteristic
H-6 (d 6.01) and H-7 correlation in the COSY spectrum implied aenins by Cunninghamella blakesleeana.
Fig. 2. Biotransformation products of neoruscogenin by Neosartorya hiratsukae.
Table 1
1H- NMR data of metabolites 1e7.
Position 1 2 3 4 5 6 7
dH (ppm), J (Hz) dH (ppm), J (Hz) dH (ppm), J (Hz) dH (ppm), J (Hz) dH (ppm), J (Hz) dH (ppm), J (Hz) dH (ppm), J (Hz)
1 3.82m 3.82 dd (4/11.5) 3.79m 3.81m e 3.79m 3.92m
2 2.23, 2.59m 2.27m, 2.64m 2.27m, 2.65m 2.73m 2.94m, 3.03m 2.21m,2.62m 2.12m, 2.71m
3 3.92m 3.89m 3.94m 3.97m 4.23m 3.94m 3.83m
4 2.67m 2.73 d (8) 2.74m 2.69m 2.94m 2.68m 2.56m
5
6 5.97 bs 6.01 s 6.02 s 6.07 d (3.6) 6.03 s 5.59 d (6.5) 5.55 d (4.6)
7 4.94m 4.14m 1.95m 1.84m
8 2.32 dd (8.8, 12.0) 2.97m 2.61m 1.79m 2.59 dd (11.5/12.0/
13.0)
2.22m 1.54m
9 2.45m 2.97m 1.96m 2.35m 2.37m 1.55m 1.51m
10
11 1.96 ddd (4.0/4.4/12.8/13.2),
2.98 d (12.8)
2.26m, 3.34m 2.05m, 3.25m 2.13 d (9.2), 3.35 dt
(3.2/7.2)
1.82m, 2.38m 2.03m, 3.30 td (5.0/5.5/
6.0/17)
2.88m, 1.38m
12 1.56m, 2.41m 4.80m 3.73m 3.79m 3.74 dd (3.0/3.5/
11.0)
3.68m 1.36m, 1.65m
13
14 1.71m 2.17m 1.67m 1.24m 1.13m
15 3.18 dd (6.4/7.2/7.2), 2.47m 2.40 ddd (6.0/7.0/
7.5)
3.60 ddd (6.0/7.5/
7.5)
1.90m, 3.38m 1.71m
2.65m
1.92m
3.37 dddd (6.0/7.0/
7.5)
1.63m, 1.96m 1.42m, 1.98m
16 5.17 ddd (7.2/7.2/7.6) 5.21 ddd (7/7.5) 4.79m 4.69 ddd (7.5/7.5/8.0) 4.77m 4.59 ddd (9.0/9.0/10.5) 4.43m
17 2.81 dd (6.8/7.6) 3.14m 2.42m 2.28m 2.40m 2.18m 1.76m
18 1.20 s 1.34 s 1.19 s 1.24 s 1.17 s 1.15 s 0.86 s
19 1.39 s 1.48 s 1.44 s 1.36 s 1.46 s 1.34 s 1.24 s
20 2.12 dd (6.8/6.8) 2.35m 2.53m 2.25m 2.53m 2.22m 1.91m
21 1.11 d (6.8) 1.44 d (7) 4.12m 1.43 d (6.4) 4.04m 1.38 d (6) 1.03 d (6.5)
22
23 1.83m 1.83m 1.87m 1.81m 1.86m 1.81m 1.85m
24 2.25m, 2.73m 2.26m, 2.73 d (8) 2.22m, 2.66m 1.72m 2.19m, 2.66m 2.25m, 2.73m 2.23m, 2.67m
25 1.56m
26 3.96 d (12), 4.42 d (12) 4.00 d (12.5), 4.45 d
(7.0)
3.95 d (12), 4.42 d
(12)
3.54m, 3.69m 3.93 d (12), 4.41 d
(12.5)
4.04 d (12), 4.49 d(12) 4.03 d (12), 4.44 d
(12)
27 4.75 d (4.8) 4.77 d (10.5) 4.75 s, 4.79 s 0.65 d (4.4) 4.74, 4.77 s 4.77 s, 4.80 s 4.79 s, 4.80 s
10 4.95 d (8)
20 4.03 dd (7.5/9.5)
30 4.23 t (7.5/9)
40 4.13 t (9/9.5)
50 3.93m
60 4.33m, 4.57 dd (3/
11.5)
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on the DEPT 135 and HSQC spectra, it was inferred that the d 86.9
signal was a quaternary carbon, whereas the 71.6 resonance was a
methine correlating with a proton at d 4.80. The planar structure of
2 was deduced by detailed inspection of the HMBC spectrum. The
3JH-C correlations of H3-18 (d 1.34) with C-17 (d 58.2), C-13 (d 50.8)
and two oxygenated carbon signals at d 71.6 and 86.9, helped us tolocate the hydroxyl groups at C-12 and C-14, respectively. In the
HMBC spectrum, the ketone signal at d 201.0 displayed a correlation
with d 2.97 resonance. In the HSQC spectrum, d 2.97 proton cor-
respondedwith a carbon signal at d 45.2, which was attributed to C-
9 based on its long-range correlation with H3-19 (d 1.48). Thus, as
suggested above, the carbonyl group was located at C-7. Inspecting
2D-NOESY spectrum and comparing 2's carbon NMR data with
Fig. 3. COSY and key HMBC correlations of metabolites 1, 3 and 5.
Fig. 4. Minimized energy conformer of metabolite 1 and key nOe correlations.
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configurations of the oxygenated positions. The absence of a cor-
relation between the b-oriented H3-18 (in 3 1.34) and H-12 (in 3
4.80) indicated that C-12(OH) was b-oriented, whereas the iden-
tical C-14 data of metabolites 1 and 2 (in 3 86.8 and 86.9, respec-
tively) revealed an alpha configuration for C-14(OH). Consequently
metabolite 2 was elucidated as 12b,14a-dihydroxy neoruscogenin-
7-one.
2.3. Metabolite 3
The molecular formula was found to be C27H38O7 based on the
major ion peak at m/z 497.2509 [MþNa]þ (calcd. 497.2515 for
C27H38O7Na). Initial inspection of the 1H NMR spectrum of 3
revealed the absence of characteristic secondary CH3-21 resonance
as well as appearance of two down-field signals at d 4.12 (2H) and
3.73 (1H). The HSQC spectrum showed a 1JC-H correlation between
the d 4.12 signal and a methylene-type carbon at d 63.2, suggesting
hydroxylation of C-21 to afford an oxymethylene group extending
from C-20. In the 13C NMR spectrum of 3, the identical resonances(d 201.4, 164.4 and 127.6) in comparison to 2 suggested an a,b-
unsaturated carbonyl system of C-5, C-6 and C-7, which was further
confirmed by H-6's (d 6.02) characteristic down-field shift (ca.
0.4 ppm). The new oxymethine signal at 78.4 ppm showed 3JH-C
long-distance correlationwith the singlet methyl proton of H3-18 (d
1.19) in the HMBC spectrum, assisting us to locate the other hy-
droxyl group at C-12 (Fig. 3). Moreover, the hydroxyl group at C-21
was also confirmed with the key HMBC's between C-17, C-20 and
H2-21, and C-21 to H-17. In the NOESY spectrum, H-12 (d 3.73)
displayed correlations with alpha-oriented H-14 (d 1.71) and H-17
(d 2.42), establishing b-configuration of C-12(OH). In conclusion,
the structure of metabolite 3 was determined to be 12b,21-
dihydroxy neoruscogenin-7-one.2.4. Metabolite 4
In the 1H NMR spectrum of metabolite 4; disappearance of
characteristic H-26 and H-27 signals of NR in the low-field, and
observation of a newmethyl signal in the down-field region (d 0.65)
implied that the compound was a ruscogenin derivative. Corre-
spondingly, loss of the characteristic olefinic signals (C-25 and C-
27) of neoruscogenin with an additional methyl resonance at
17.1 ppm in the 13C NMR spectrum, and the major ion peak at m/z
463.3059 [MþH]þ (463.3060 calcd.) in the HR-MS spectrum sub-
stantiated our first impression of 4 being a ruscogenin metabolite.
The mass data exhibiting 32 amu increase over ruscogenin, and
appearance of two additional carbon signals at d 79.1, 64.2 sug-
gested hydroxylations. In the HMBC spectrum, the 3JH-C correlations
of characteristic H3-18 resonance (d 1.24) with C-13 (45.5), C-14
(49.0), C-17 (62.9) and the new signal at d 79.1 (C-12) verified the
position of first hydroxylation at C-12. In the COSY spectrum, a
strong correlation from olefinic signal at d 6.07 (H-6) with the new
resonance at d 4.14 (H-7) helped us to locate the second hydroxyl
€O. €Ozçinar et al. / Phytochemistry 152 (2018) 1e9 5group at C-7. To determine the relative stereochemistry of 4, 2D-
NOESY and ROESY spectra were inspected. The correlation of H-12
with alpha oriented H-9 (d 2.35), and a cross peak between H-7 and
beta oriented H-8 (d 1.79) revealed the configurations of OH groups.
As a result, metabolite 4 was established as 7a,12b-dihydroxy
ruscogenin.
2.5. Metabolite 5
The molecular formula of 5 was determined to be C27H36O7
based on the major ion peak at m/z 495.2363 [MþNa]þ. In the 1H
NMR spectrum of 5, together with characteristic NR signals, three
additional low-field proton signals (d 4.23, 4.04, 3.74) were
observed. The disappearance of distinctive secondary methyl group
(C-21) was also noticed readily as in metabolite 3. Besides, 13C NMR
and DEPT135 revealed extra signals in the low-field: two carbonyl
resonances (d 208.2, 199.7), an oxymethine (d 77.8) and an oxy-
methylene (d 63.2). On the basis of these data, it was evident that,
C-21 and an additional position were hydroxylated on the NR
framework. Ketone formation at C-7 position was clear due to
deshielding of H-6 (d 6.03) and C-5 (d 159.8). However, C-5's ca.
5 ppm up-field shift compared to those of 2 and 3 implied an
alteration on the ring A. In the HMBC spectrum (Fig. 3), strong 3JH-C
correlations of H3-19 (d 1.46) with d 208.2, C-5 (d 159.8), C-9 (d 42.1)
and C-10 (d 54.2) signals suggested oxidation of the secondary
alcohol at C-1, whereas the correlation of H3-18 (d 1.17) with the
new oxygenated methine carbon at d 77.8 implied the second hy-
droxylation position as C-12. All of these deductions were also
verified by establishing the spin systems of metabolite 5 via ex-
amination of the COSY, TOCSY and HSQC spectra: SS1/ H2-2/H-
3(O)/H2-4 (A ring); SS2 / H-12(O)/H-11/H-9/H-8/H-14/H2-15/H-
16(O)/H-17/H-20/H2-21; SS3/ H2-23/H2-24 SS4/ H2-27 (allylic
coupling)/H2-26(O). The stereochemistry of the hydroxyl group at
C-12 was determined by examining the NOESY and ROESY spectra,
which exhibited a cross peak from alpha oriented H-14 (d 1.67) to
H-12 (d 3.74) confirming the orientation of C-12(OH) as beta. On the
basis of these evidence, the structure of compound 5 was eluci-
dated as 12b,21-dihydroxy neoruscogenin-1,7-dione.
Metabolites 6 and 7 were obtained from the biotransformation
study of N. hiratsukae.
2.6. Metabolite 6
The HR-MS spectrum of 6 provided a major ion peak at m/z
445.2949, indicating 16 amu increase over NR. In the 1H NMR
spectrum of 6, in addition to the characteristic low-field signals of
neoruscogenin, an additional resonance at d 3.68 was observed
(Table 2). In the 13C NMR and DEPT135 spectra, the additional
oxymethine signal at d 79.3 undoubtedly demonstrated mono-
hydroxylation on the skeleton, while a key HMBC between the new
oxymethine carbon signal and H3-18 methyl group (d 1.15) helped
us locating the hydroxyl group at C-12. The relative configuration at
the new stereocenter was established based on the NOESY data,
displaying correlations between H-12 (d 3.68) and b-oriented H3-
18/H-20 protons (d 1.15 and 2.22, respectively). Consequently, the
structure of 6 was determined to be 12a-hydroxy neoruscogenin.
2.7. Metabolite 7
In the HR-MS of 7, the major ion peak was observed at m/z
613.3353 [MþNa]þ (calcd. 613.3353 for C33H50O9Na), which was
suggesting glycosidation of the neoruscogenin skeleton due to 162
amu difference (C6H10O5). Inspection of the 1H NMR spectrum
revealed an anomeric proton at d 4.95 (d, J¼ 8.0 Hz), whereas the
additional resonances in the 13C NMR spectrum deriving from ahexose unit were consistent with the presence of a b-glucopyr-
anosemoiety. Comparing the spectral data of 7with neoruscogenin
and the other metabolites, the significant down-field shift of C-1 (d
82.9, Dppm¼ 6e8) helped us locating the glucopyranose unit.
Additionally, the 3JH-C correlation of C-1 (d 82.9) with the anomeric
proton signal (d 4.95) in the HMBC spectrum verified the glyco-
sidation site as C-1. On the basis of these results, the structure of 7
was established as neoruscogenin-1-O-b-glucopyranoside.
2.8. Metabolites 8, 9a, 9b and 10
Metabolites 8e10were not brought to a good state of purity due
to purification difficulties. However, the structures of these me-
tabolites were identified based on detailed inspection of 1- and 2D
NMR spectra.
The major ion peak at m/z 483.2717 [MþNa]þ in the HR-MS
spectrum of metabolite 8 displayed 32 amu increase over NR,
suggesting a dihydroxy analog. In the low-field region of the 1H
NMR spectrum, two additional low-field protons (d 3.27 and 3.65)
were observed (Table 3). Besides, in the 13C NMR spectrum, two
extra down-field carbon signals at d 72.7 and 80.3 were also noted.
In order to deduce oxidation positions, the 2D NMR spectra were
inspected in detail. Full assignments of the proton and carbon
signals of 8 secured by the COSY and HSQC spectra implied the
position of hydroxylations as C-7 and C-12. In the HMBC spectrum,
the long-range correlations of the olefinic carbon signals at 141.4
and 130.9 ppm (C-5 and C-6, respectively) with H-7 (d 3.65), and C-
12 (d 80.3) and H3-18 (d 0.81) verified the proposed trans-
formations. For establishing stereochemistry of 8, a 2D-NOESY
experiment was performed. Alpha oriented H-9 (d 1.35) exhibited
correlations with H-7 (d 3.65) and H-12 (d 3.27), while H-17a (d
1.87) correlated with H-12, substantiating co-facial orientation of
C-7 and C-12 OH groups as b. Based on these findings, the structure
of 8 was determined as 7b,12b-dihydroxy neoruscogenin. In the 1H
NMR spectrum of 9, appearance of two distinctive H-16 signals and
presence of characteristic methyl resonances for both starting
frameworks (R and NR) point to a mixture of two metabolites, NR
being the major one (9a). In the 13C NMR spectrum, similar with
metabolite 4, a weak methyl resonance at 16.2 ppm was attributed
to the C-27 of the minor ruscogenin metabolite (9b). These sug-
gestions were also substantiated with a major peak atm/z 459.2732
[MþH]þ and a minor peak at 461.3885 [MþH]þ in the HR-MS
spectrum, indicating 30 amu difference compared to NR and R,
respectively. All the proton and carbon resonances of metabolite 9a
were secured by COSY, HSQC and HMBC spectra, verifying C-12
hydroxylation as in 2e5 and 8, and oxidation of C-7 to give ketone
functionality as in compounds 2, 3 and 5. In the case of stereo-
chemical assignment of C-12(OH), the chemical shift and coupling
constant values obtained for metabolite 1 and 9a were taken into
consideration, revealing same configuration for both compounds as
beta for the hydroxyl group. This suggestion was also substantiated
with the nOe correlation of H-12 (d 3.25) and alpha oriented H-9 (d
1.79), H-14 (d 1.41) and H-17 (d 1.84) resonances in the 2D-NOESY
spectrum. When the 1D and 2D-NMR spectra were also inspected
for the minor constituent 9b, completely identical structural con-
clusions were achieved for ruscogenin skeleton. Consequently,
metabolites 9a and 9b were elucidated as 12b-hydroxy neo-
ruscogenin-7-one and 12b-hydroxy ruscogenin-7-one, respec-
tively. The HR-MS spectrum of 10 provided a major peak at m/z
481.2566, [MþNa]þ (calcd. 481.2566), supporting a molecular for-
mula of C27H38O6Na. In the 1H NMR spectrum, in addition to typical
neoruscogenin signals, the appearance of a proton resonance at
d 4.09, which was correlating with d 70.6 resonance in the HSQC
spectrum, implied transformation of a methylene carbon to oxy-
methine carbon via hydroxylation in the steroid framework. This
Table 2
13C NMR data of metabolites 1e7.
Position 1 2 3 4 5 6 7
dc (ppm) dH (ppm) dH (ppm) dH (ppm) dH (ppm) dc (ppm) dc (ppm)
1 78.3 76.2 76.3 77.4 208.2 77.8 82.9
2 43.9 42.9 42.7 43.4 48.2 43.2 37.3
3 68.2 66.1 66.3 67.3 66.6 67.9 67.8
4 43.9 43.3 43.4 44.2 41.5 43.6 43.2
5 140.7 165.6 164.4 142.9 159.8 140.1 139.2
6 132.1 128.4 127.6 128.1 127.5 124.2 124.7
7 67.3 201.0 201.4 64.2 199.7 31.9 31.7
8 45.7 48.9 44.7 37.7 43.9 42.7 32.8
9 43.9 45.2 49.6 42.7 42.1 50.6 50.1
10 44.1 45.2 45.2 43.5 54.2 43.5 42.3
11 24.0 33.6 30.6 34.1 30.7 34.2 23.8
12 33.1 71.6 78.4 79.1 77.8 79.3 40.0
13 46.0 50.8 46.4 45.5 47.1 45.7 40.0
14 86.8 86.9 48.8 49.0 49.0 55.2 55.8
15 43.4 42.1 32.2 31.7 33.6 31.9 32.1
16 83.1 82.5 82.6 81.1 82.4 81.3 81.2
17 59.9 58.2 59.4 62.9 59.4 62.8 62.8
18 20.7 14.0 11.0 11.3 10.9 11.1 10.9
19 13.9 12.0 11.7 12.6 16.8 13.7 14.0
20 42.4 42.9 50.2 42.7 59.6 42.7 41.7
21 15.7 14.5 63.2 14.2 63.2 14.1 14.6
22 110.1 109.9 108.9 109.3 109.2 109.5 109.4
23 33.8 33.2 33.8 30.4 33.6 33.1 31.8
24 29.4 28.8 29.4 31.7 28.6 28.8 28.9
25 144.9 144.3 142.2 29.0 143.8 144.3 144.2
26 65.3 64.7 63.1 73.8 64.5 64.8 63.4
27 108.9 108.5 109.0 17.1 108.8 108.4 108.5
10 101.2
20 75.2
30 78.3
40 72.1
50 77.9
60 63.4
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relation to characteristic olefinic signal of H-6 (d 5.93) in the COSY
spectrum. As well, a carbonyl signal at d 213.3, which was lacking in
the 13C NMR spectrum due to its low intensity, displayed a strong
long-range correlation with the methyl resonance at d 1.20. The
latter was assigned to H3-18 because of its long-range correlation to
C-17, which also exhibited 3JH-C correlation to H3-21. As a result of
these key HMBC's, the position of the carbonyl group was secured
as C-12. The beta oriented hydroxyl group at C-7 was readily
deduced via the correlation of alpha oriented H-14 (d 1.92) with H-7
(d 4.09) in the NOESY spectrum. Thus, the structure of 10 was
determined as 7b-hydroxy neoruscogenin 12-one.
3. Conclusions
Recent studies performed on steroids showed that Cunning-
hamella species have high catalytic activity (Baydoun et al., 2017;
Xiao et al., 2011; Xu et al., 2015), which can also be used for
investigating the metabolism of drugs because of their abilities of
catalyzing Phase I and II reactions similar to the mammalian
enzyme systems. In continuation of our biotransformation studies
performed on ruscogenins by C. blakesleeana (€Ozçinar et al., 2016), a
number of previously unreported compounds were obtained. The
compounds were mainly hydroxylation products including C-7, C-
12, C-14 and C-21 positions, whereas further oxidations at C-1 and
C-7 were encountered.
All the metabolites were C-7 hydroxylated or oxidized analogs
as parallel to other studies performed on steroidal compounds
(Ahmad et al., 2017; Kozlowska et al., 2017; Xu et al., 2015). This
modification, catalyzed by fungal CYP450 monooxygenase and
dehydrogenase enzymes, readily takes place due to the allylicnature of C-7 position (Ortiz de Montellano and Nelson, 2011).
Additionally, another major hydroxylation location was C-12,
except compound 1. Interestingly, this transformation was stereo-
selective [12-b(ΟН)] compared to the regioselective C-7 hydroxyl-
ation. The monooxygenation reactions occurred at the tertiary C-14
(1 and 2) and C-21 methyl group (3 and 5) have been encountered
rarely on steroidal framework, as non-reactive centers, they are
challenging positions for modification via chemical synthesis
(Faramarzi et al., 2008; Kolet et al., 2014; Lamm et al., 2007; Wu
et al., 2011).
In order to exploit the catalytic capacity of the endophytic fungi
to obtain new neoruscogenin derivatives, N. hiratsukaewas utilized,
providing CYP450 monooxygenase products mainly as in
C. blakesleeana study. Moreover, observation of further oxidation at
C-12 to yield ketone functionality (10) and the phase II metabolite 7
as glycosylated derivative were noteworthy.
Further studies are in progress with different endophytic fungi
to include more compounds to the metabolite library, as well
bioactivity studies are being pursued for the compounds with
sufficient quantity.
4. Experimental
4.1. General experimental procedures
Mass spectrometry analysis was performed on an Agilent 1200/
6530 Instrument eHRTOFMS. The 1D and 2D NMR spectra were
obtained on Varian Oxford AS400 and Bruker DRX-500 in-
struments. Proton and carbon chemical shifts are relative to the
solvent signals. Column chromatography experiments were carried
out on silica gel 60 (40e63mm-Merck), Sephadex LH-20 (GE
Table 3
1H and13C NMR data of metabolites 8e10.
Position 8 9a(9b) 10
dH (ppm), J (Hz) dc (ppm) dH (ppm), J (Hz) dc (ppm) dH (ppm), J (Hz) dc (ppm)
1 3.38m 78.5 3.49 dd (4.5/12) 75.8 3.70m 76.8
2 1.61m, 1.97m 42.5 1.71m, 2.10m 40.8 2.21m, 2.60m 42.8
3 3.44m 68.6 3.57m 65.8 3.94m 67.2
4 2.23m 42.8 2.40 dd (11.5/13.0) 41.8 2.65m 42.9
5 141.4 164.7 104.2
6 5.42 s 130.9 5.80 s 126.9 5.93 s 130.7
7 3.65 d (10.5) 72.7 202.6 4.09m 70.6
8 1.49m 40.8 2.45m 44.1 2.23m 40.4
9 1.35 ddd (3.6/4.4/7.6) 48.3 1.79m 49.4 1.94m 42.3
10 43.8 44.8 50.5
11 1.54m, 2.51m 34.2 2.27m, 2.55m 32.6 2.95m, 3.66 d (5) 40.3
12 3.27 dd (4.0/4.4/6.4) 80.3 3.25m 77.9 213.3
13 47.0 47.7 55.5
14 1.22m 55.7 1.41m 29.8 1.92m 42.3
15 1.66m, 2.35m 35.0 1.50m, 2.84m 32.6 2.25m, 2.95m 34.5
16 4.45 ddd, (7.2/7.6/7.2) 82.8 4.51 ddd (6.5/7.5/8.0/8.5) 81.2 4.55 ddd (7.0/7.0/8.5) 80.6
17 1.87m 62.7 1.84m 60.8 2.85m 53.5
18 0.81 s 11.3 0.80 s 9.7 1.20 s 15.8
19 1.10 s 13.5 1.29 s 10.6 1.31 s 12.7
20 1.91m 43.7 1.91m 42.3 1.94m 42.3
21 1.02 d (6.1) 14.0 1.04 d (7.5) 12.8 1.29 d 14.0
22 110.8 109.6 108.5
23 1.74m 34.1 1.73m 32.6 1.78m 33.3
24 2.26m, 2.57m 29.5 2.27m, 2.55m
[1.71m]
28.1 2.24m, 2.68m 29.4
25 145.3 [1.62m] 143.7 [28.5] 143.9
26 3.83 d (11.8), 4.28 d (12.5) 65.9 3.85 d (12), 4.30 d (12)
[3.37 d 11.0]
[3.48 dd 4.5/11.7]
64.4 [66.5] 4.01 d (13), 4.43 d (12) 64.6
27 4.73 s, 4.77 s 108.9 4.76 s, 4.79 s
[0.81 d 4.1]
107.8 [16.1] 4.77 s, 4.82 s 109.1
*Compounds 9a and 9bwere isolated as amixture for whichmost of the 1H NMR datawere superimposable. Themost distinguishing 1H NMR data of theminormetabolite [9b]
are given above.
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carried out on Silica gel 60 F254 (Merck) and RP-18 F254s (Merck)
plates. Compounds were detected by UV and 20% H2SO4/water
spraying reagent followed by heating at 105 C for 1e2min. Optic
rotations were measured using Perkin-Elmer 341 polarimeter.
4.2. Microorganisms and the lead compounds
C. blakesleeana NRRL 1369 was obtained from the ARS Culture
Collection, USA. Neosartoria hiratsukae, an endophytic fungus iso-
lated from Astragalus angustifolius (Ekiz, 2016), was also selected
for preparative scale biotransformation. Ruscogenins (NR to R ratio
was 75:25) and neoruscogenin (>95%) was donated by Bionorm
Natural Products Ltd. (Izmir, Turkey).
4.3. Microbial transformation procedures
The biotransformation process was conducted at two scales
analytical and preparative. Stock cultures of C. blakesleeana and
N. hiratsukae stored at þ4 C were revived on PDA (Potato-
dextrose-agar) slants at 30 C and 25 C, respectively. Inoculum of
2% derived from the suspension of 5e7 days old cultures with
Tween 80 (0.1%), was used in the biotransformation process. One-
stage fermentation protocol was followed where ruscogenins/
neoruscogenin were fed to the biotransformation media 72 h after
the inoculation. The biotransformation media contained 2%
glucose, 0.5% yeast extract, 0.5% NaCl, 0.5% K2HPO4 and 0.5% (w/v)
peptone (pH 6.0). Analytical scale was conducted using 250ml
flasks containing 50ml of media and 10mg of ruscogenins. Every 2
days, samples with a volume of 0.5ml were taken and centrifuged.
Then the supernatants were extracted with ethyl acetate. In orderto differentiate the transformed products from the metabolites of
the microorganisms, one flask was kept in same condition with no
lead compound. In preparative scale, 1 L flasks containing 200ml of
media and 40mg of substrate used in same conditions. In the
C. blakesleeana NRRL 1369 study at preparative scale, 640mg of
ruscogenins was used (30 C, 180 rpm, 10 days), whereas in the
N. hiratsukae preparative experiment, 1.48 g of neoruscogenin was
fed (25 C, 180 rpm, 10 days).
4.4. Extraction and isolation
After the incubation period, separation of the microorganisms
from the growth media was first step. This process was carried out
by using vacuum filtration, and then the broths were extractedwith
both ethyl acetate (3 times) and n-butanol. Ethyl acetate extracts
were dried over anhydrous sodium sulfate. Then the organic layers
were combined and evaporated under vacuum. By comparing with
the reference sample of ruscogenins/neoruscogenin and the blank
sample, the biotranformation products were identified on thin
layer chromatography (TLC) plates.
Compounds 1e5 and 8, 9 were isolated from the EtOAc extract
(712mg) of C. blakesleeana and Ruscogenins. This extract was
applied to reverse phase flash column chromatography (40 g, 5ml/
min; 30%; ACN:H2O), which provided 14 main fractions. Fraction A
(27.7mg) was subjected to normal phase silica gel column (1.5/
16 cm; 12 g) using CHCl3:MeOH:H2O (95:5:0.5) for the further pu-
rifications. This afforded 2mg 1 and 0.5mg 2. To obtain metabolite
8, fraction B (39mg) was precipitated in acetonitrile to give 10.5mg
of 8. The supernatant was evaporated (22mg), and was applied to
open column chromatography containing normal phase silica gel
(1.5/14 cm; 10 g) with Hex:EtOAc:MeOH solvent system (10:10:2)
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to silica gel (2/13 cm; 15 g) eluting with CHCl3:MeOH (90:10) to
give 15mg of 9 (mixture of 9a and 9b), and 3mg of 5. Compounds 6,
7 and 10were isolated from the combined EtOAc and BuOH extract
(4.87 g) of N. hiratsukae and neoruscogenin. The crude extract was
divided into two parts, and each was applied to Sephadex-LH 20
column (3/48 cm, 100 g; 100% MeOH). Fractions 31e46 and 30e42,
which had NR metabolites, were pooled together for further puri-
fication. The combined fraction was subjected to silica gel chro-
matography (3/27.5 cm, 80 g) eluting with gradient of MeOH in
CHCl3 (increasing polarity from 100:0 to 80:20, CHCl3:MeOH) and
yielded 25 main fractions. The fraction A precipitated by ACN and
20mg NR have been recovered. For further purification; fraction B
(48.5mg) was applied to VLC containing reverse phase silica gel (3/
8 cm; 20 g), eluted with gradient of Acetonitrile:H2O (%20e50 ACN)
to give 6 (11mg) and 10 (4mg). The fractions containingmetabolite
7 (50mg) was subjected to silica gel chromatography (2/17 cm,
15 g), and elution with CHCl3:MeOH (90:10) afforded 15mg of 7.
4.5. Compound characterization
7b,14a-dihydroxy neoruscogenin [Spirosta-5,25(27)-dien-
1b,3b,7b,14a-tetraol] (1): White amorphous solid. [a]D25: 132 (c
0.03, MeOH). 1H NMR (pyridine-d5, 400MHz): see Table 1; 13C NMR
(pyridine-d5, 100MHz): see Table 2; HR-MS: m/z 461.2899 [MþH]þ
(C27H41O6, calcd. 461.2903).
12b,14a-dihydroxy neoruscogenin-7-one [Spirosta-5,25(27)-
dien-1b,3b,12b-14-tetraol-7one] (2): White amorphous solid.
[a]D25: 91 (c 0.04, MeOH). 1H NMR (pyridine-d5, 500MHz): see
Table 1; 13C NMR (pyridine-d5, 125MHz: see Table 2; HR-MS: m/z
497.2531 [MþNa]þ (C27H38O7Na, calcd. 497.2515).
12b,21-dihydroxy neoruscogenin-7-one [Spirosta-5,25(27)-
dien-1b,3b,12b, 21-tetraol-7-one] (3): White amorphous solid.
[a]D25: 25 (c 0.07, MeOH). 1H NMR (pyridine-d5, 500MHz): see
Table 1; 13C NMR (pyridine-d5, 125MHz): see Table 2; HR-MS: m/z
497.2509 [MþNa]þ (C27H38O7Na, calcd. 497.2515).
7a,12b-dihydroxy ruscogenin [Spirosta-5-en-1b,3b,7a,12b-tet-
raol] (4): White amorphous solid. [a]D25: 122 (c 0.07, MeOH). 1H
NMR (pyridine-d5, 500MHz): see Table 1; 13C NMR (CD3OD,
125MHz): see Table 2; HR-MS: m/z 463.3059 [MþH]þ (C27H43O6,
calcd. 463.3060).
12b,21-dihydroxy neoruscogenin-1,7-dione [Spirosta-5,25(27)-
dien-3b,12b,21-triol-1,7-dione] (5) White amorphous solid.
[a]D25: 73 (c 0.03, MeOH). 1H NMR (pyridine-d5, 500MHz): see
Table 1; 13C NMR (pyridine-d5, 125MHz): see Table 2; HR-MS: m/z
495.2363 [MþNa]þ (C27H36O7Na, calcd.465.2359).
12a-hydroxy neoruscogenin [Spirosta-5,25(27)-dien-1b,3b,12a-
triol] (6) White amorphous solid. [a]D25: 46 (c 0.07, MeOH). 1H
NMR (pyridine-d5, 500MHz): see Table 1; 13C NMR (pyridine-d5,
125MHz): see Table 2; HR-MS: m/z 445.2950 [MþH]þ (C27H41O5,
calcd. 445.2954).
Neoruscogenin-1-O-b-glucopyranoside [Spirosta-5,25(27)-
dien-1b,3b,diol-1-O-b-glycopyranoside (7): White amorphous
solid. [a]D25: 33 (c 0.07, MeOH). 1H NMR (pyridine-d5, 500MHz):
see Table 1; 13C NMR (pyridine-d5, 125MHz): see Table 2; HR-MS:
m/z 613.3353 [MþNa]þ (C33H50O9Na, calcd. 613.3353).
7b,12b-dihydroxy neoruscogenin [Spirosta-5,25(27)-dien-
1b,3b,7b,12b-tetraol] (8): White amorphous solid. [a]D25: 118 (c
0.07, MeOH). 1H NMR (CD3OD, 400MHz): see Table 3; 13C NMR
(CD3OD, 100MHz): see Table 3; HR-MS: m/z 483.2717 [MþNa]þ
(C27H40O6Na, calcd. 483.2723).
Mixture of 12b-hydroxy neoruscogenin-7-one and 12b-hydroxy
ruscogenin-7-one [Spirosta-5,25(27)-dien-1b,3b,12b-triol-7-one
and Spirosta-5-en-1b,3b,12b-tetraol-7-one, respectively] (9a and
9b): White amorphous solid. [a]D25: 91 (c 0.07, MeOH). 1H NMR(CD3OD, 500MHz): see Table 3; 13C NMR (CD3OD, 125MHz): see
Table 3; HR-MS: m/z 459.2732 [MþH]þ for 9a (C27H39O6,
calcd.459.2747) m/z 461.2885 [MþH]þ for 9b (C27H41O6,
calcd.461.2747).
7b-hydroxy neoruscogenin 12-one [Spirosta-5,25(27)-dien-
1b,3b,7b-triol-12-one] (10): White amorphous solid. [a]D25: 142 (c
0.07, MeOH). 1H NMR (pyridine-d5, 500MHz): see Table 3; 13C NMR
(pyridine-d5, 125MHz): see Table 3; HR-MS: m/z 481.2566
[MþNa]þ (C27H38O6Na, calcd.481.2566).
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